Catalent Inc (NYSE:CTLT)
$ 55.61 0.09 (0.16%) Market Cap: 10.06 Bil Enterprise Value: 14.88 Bil PE Ratio: 0 PB Ratio: 2.79 GF Score: 81/100

Catalent Inc at UBS Global Healthcare Virtual Conference Transcript

May 26, 2021 / 03:00PM GMT
Release Date Price: $104.29 (+0.81%)
Daniel Gregory Brennan
UBS Investment Bank, Research Division - Senior Equity Research Analyst of Healthcare Life Sciences

Welcome. Dan Brennan here on day 3 of the UBS Global Healthcare Conference. Hopefully, it's been a great event for all of you joining on the webcast. Pleased to be joined here in the 11:00 hour with senior management of Catalent, which is a buy-rated stock here, has been one of our top picks -- actually, published as a top -- as our top pick today, global or a U.S.-oriented research note that was put out by our strategist.

Really pleased to be joined by 2 members of the management team. We have Tom Castellano. Tom, who was -- I got to know in his previous role as -- in Investor Relations and subsequent to that, migrating back into the company and now is recently appointed Chief Financial Officer. So really pleased to have Tom here to be speaking on Catalent's behalf; as well we have Paul Surdez, who's Head of Investor Relations. (Operator Instructions) I'll check it throughout the presentation here.

So maybe, Tom, listen, congratulations on being appointed the new

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot